28 results
8-K
EX-99.1
LHDXQ
Lucira Health, Inc.
12 Jun 23
Other Events
4:02pm
of medical product development. These include research, development, testing, and manufacture and quality control. Additional regulated aspects include import … to Pay Certain Prepetition Claims Related to Research and Development; (II) Authorizing the Debtor to Continue the NIH Grant Program in the Ordinary
8-K
EX-99.1
LHDXQ
Lucira Health, Inc.
14 Nov 22
Lucira Health Announces Third Quarter 2022 Results and Provides Business Updates
5:20pm
and development expense during the third quarter of 2021 and subsequently sold at zero cost of product and internally consumed in research and development … and foreign countries; our research and development for any future test kits; the development, regulatory approval, and commercialization of competing
8-K
EX-99.1
LHDXQ
Lucira Health, Inc.
15 Aug 22
Lucira Health Announces Second Quarter 2022 Results and Provides Business Updates
5:27pm
recorded as research and development expense during the third quarter of 2020 and subsequently sold at zero cost of product and internally consumed … in research and development and sales and marketing from the fourth quarter of 2020 through the third quarter of 2021.
Forward Looking Statements
8-K
EX-99.1
tad7ew130brm
12 May 22
Lucira Health Announces First Quarter 2022 Results and Business Update
4:20pm
DEF 14A
web6lkmj
20 Apr 22
Definitive proxy
4:12pm
8-K
EX-99.1
kfp 0g7bbk
10 Mar 22
Lucira Health Announces Fourth Quarter and Full Year 2021 Results and Reaffirms 2022 Financial Outlook
5:15pm
8-K
EX-99.1
as86cytzlyk8bohs
12 Nov 21
Lucira Health Announces Third Quarter 2021 Financial Results and Provides Business Update
6:04am
8-K
EX-10.1
gqb8lben0 g2nub
27 Aug 21
Departure of Directors or Certain Officers
5:06pm
8-K
EX-99.1
65te687plh8o3
12 Aug 21
Lucira Health Announces Second Quarter 2021 Financial Results
4:06pm
8-K
EX-99.1
8m8ffyt4a2vh2qdvydqg
18 May 21
Lucira Health Announces First Quarter 2021 Financial Results
12:08pm
10-Q
hppyh54mklchgdh1f
17 May 21
Quarterly report
4:17pm
10-K
pz9t057n2y
31 Mar 21
Annual report
5:16pm
424B4
4t9zdmass6na7qjh2n0
8 Feb 21
Prospectus supplement with pricing info
11:06am
S-1/A
EX-1.1
c2u6g63r4xh4wt1oywc
1 Feb 21
IPO registration (amended)
7:58am